*A summary of Pathway Capital’s whitepaper on regulatory strategy in early-stage life science investment
There is a gap in how many early-stage biotech founders present their products and in how life science investors make decisions. It is not a gap in scientific rigour, market analysis, or team assessment. Those disciplines have grown considerably more sophisticated over the past two decades. The gap is in a regulatory strategy needed to identify and derisk uncertainties on the path to market. For biotechs, medtech, and pharma startups this means a good hard look at what could be lurking on the critical path to licensure. This compounds into a need for early integration of a regulatory framework designed for each product in development. Without this critical activity in the earlier stages of a venture, the evidence suggests it is costing investors, ventures, and patients more than most frameworks currently account for.
The Core Problem
Regulatory pathway decisions made at or before the point of investment are among the most consequential in a venture’s lifecycle. Which approval pathway a company pursues, how it sequences its evidence, when it engages with agencies — these choices shape timelines, capital requirements, and ultimately whether a product reaches patients at all.
Yet across every investor type — venture capital, private equity, institutional asset managers, angel groups, family offices, philanthropic foundations, and development finance institutions — regulatory strategy is treated as a downstream operational concern rather than a core investment variable. It gets picked up after the cheque is written, not before.
What the Evidence Shows
The consequences are measurable. When regulatory strategy is underweighted at points of investment, the results tend to follow a predictable pattern: extended holding periods, unplanned dilution rounds, failed exits, and delayed patient access. The holding period erosion alone is material for venture capital funds whose internal rate of return (IRR) is acutely sensitive to time.
The flip side is equally consistent. Ventures where regulatory strategy was integrated early demonstrate better capital efficiency, stronger exit positioning, and faster routes to the patients who need their products. The pathway chosen at the outset compounds, in both directions.
It Is Not Just a Venture Capital Problem
One of the more underappreciated dimensions of this issue is how far it extends beyond early-stage venture. Private equity firms pursuing growth-stage and buyout strategies in life sciences face a distinct but equally material form of regulatory exposure — post-approval label scope, post-market obligations, platform consolidation risk — that is largely absent from published deal frameworks. Regulatory diligence at acquisition is frequently outsourced or omitted entirely.
The same pattern holds across institutional investors, family offices, and philanthropic foundations. Each investor type has a different return objective and a different relationship to risk — but all share a common dependency: the ventures they back must navigate a regulatory pathway to generate value. That dependency is rarely modelled explicitly.
Why the Gap Persists
This is not a critique of investor practice. Regulatory strategy is genuinely complex. Deep expertise is scarce. And the frameworks for integrating it into investment decision-making have, until recently, been underdeveloped. Most investors rely on ad hoc external consultants or simply defer the question until after commitment.
The result is a systematic blind spot —not from negligence, but from the absence of the right tools and reference points at the right moment in the decision process.
What Good Looks Like
The evidence points toward a clear direction of travel. Integrating regulatory strategy earlier — as a diligence input alongside science quality, market sizing, and team assessment — produces better outcomes across financial performance, approval success rates, and speed of patient access.
That integration does not require every investor to develop in-house regulatory expertise. It requires the right questions to be asked at the right stage, supported by practitioners who can translate regulatory complexity into investment-relevant language.
The Logical Next Step
What remains missing is a framework based on an empirical foundation: a longitudinal study quantifying these relationships across a defined investment cohort, with the precision needed to give decision-makers reliable probability estimates for technical and regulatory success across global markets. That work is the next step — and the one most likely to shift practice at scale.
The case, in the meantime, is already clear. Regulatory strategy is not a compliance checkbox. It is a variable that predicts venture outcome quality, and one that the best-positioned founders and investors will treat accordingly.
—
*This post is based on the Pathway Capital’s whitepaper: “Regulatory Strategy in Early-Stage Life Science Investment: Evidence, Impact, and the Case for Earlier Integration.” Pathway Capital is a Cambase Life Sciences initiative. Nothing in this post constitutes investment advice.*